Faculty

Back to Index
Lon Schneider, MD
Professor of Psychiatry & The Behavioral Sciences
Psychiatry and The Behavioral Sciences
CHP-216 1540 Alcazar Street Health Sciences Campus Los Angeles
+1 323 442 7600

Overview

Lon Schneider, MD, MS is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California. He is director of the California Alzheimer's Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health). In addition, he is principal investigator of the National Institute of Mental Health's CATIE program, a multicenter effectiveness trial of atypical antipsychotics in Alzheimer's disease.

Awards

Woodward/White, Inc.: The Best Doctors in America, 1992-2009

Publications

Challenging Assumptions About African American Participation in Alzheimer Disease Trials. Am J Geriatr Psychiatry. 2017 Oct; 25(10):1150-1159. View in: PubMed

Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor ß-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women. Menopause. 2017 Sep 18. View in: PubMed

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017 Sep; 49(9):1373-1384. View in: PubMed

Lessons from the Multidomain Alzheimer Preventive Trial. Lancet Neurol. 2017 Aug; 16(8):585-586. View in: PubMed

Preventing Dementia: Many Issues and Not Enough Time. JAMA Neurol. 2017 May 01; 74(5):508-510. View in: PubMed

Dementia research priorities-1 - Author's reply. Lancet Neurol. 2017 Mar; 16(3):181. View in: PubMed

Dementia research priorities-2 - Author's reply. Lancet Neurol. 2017 Mar; 16(3):182. View in: PubMed

Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E e4 Carriers: A Review. JAMA Neurol. 2017 Mar 01; 74(3):339-347. View in: PubMed

Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimers Res Ther. 2017 Feb 17; 9(1):10. View in: PubMed

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 2017 Jan; 13(1):8-19. View in: PubMed

Alzheimer's disease and other dementias: update on research. Lancet Neurol. 2017 Jan; 16(1):4-5. View in: PubMed

WHO's dementia research priorities: a prescription for failure? Lancet Neurol. WHO's dementia research priorities: a prescription for failure? Lancet Neurol. 2016 Nov; 15(12):1202-1203. View in: PubMed

R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016 Sep; 82(3):784-92. View in: PubMed

Reduce vascular risk to prevent dementia? Lancet. Reduce vascular risk to prevent dementia? Lancet. 2016 Aug 20; 388(10046):738-40. View in: PubMed

Mortality risk in current and new antipsychotic Alzheimer's disease users: Large scale Japanese study. Alzheimers Dement. 2016 Jul; 12(7):823-30. View in: PubMed

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016 Jun 30; 8:25. View in: PubMed

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016 May 01; 173(5):465-72. View in: PubMed

Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. Am J Psychiatry. 2016 May 01; 173(5):473-80. View in: PubMed

Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016 Apr; 15(5):455-532. View in: PubMed

Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. J Psychiatr Res. 2016 Mar; 74:17-21. View in: PubMed

Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64. View in: PubMed

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar; 12(3):292-323. View in: PubMed

A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. J Pharmacokinet Pharmacodyn. 2016 Feb; 43(1):99-109. View in: PubMed

Accelerating stem cell trials for Alzheimer's disease. Lancet Neurol. 2016 Feb; 15(2):219-230. View in: PubMed

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016 12 10; 388(10062):2873-2884. View in: PubMed

Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials. J Alzheimers Dis. 2016; 50(4):1205-15. View in: PubMed

Treatment changes among older patients with dementia treated with antipsychotics. Int J Geriatr Psychiatry. 2015 Dec; 30(12):1238-49. View in: PubMed

Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015 Dec; 27(12):2059-67. View in: PubMed

Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. Am J Geriatr Psychiatry. 2015 Nov; 23(11):1127-33. View in: PubMed

Estimating Mortality Associated With Antipsychotics and Other Psychotropics--Reply. JAMA Psychiatry. 2015 Oct; 72(10):1058. View in: PubMed

Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? Alzheimers Dement (N Y). Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? Alzheimers Dement (N Y). 2015 Jun; 1(1):46-52. View in: PubMed

Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015 May; 72(5):438-45. View in: PubMed

Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 2015 Mar 17; 84(11):1121-7. View in: PubMed

Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimers Dement (Amst). 2015 Mar; 1(1):103-11. View in: PubMed

Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol. 2015 Feb; 72(2):209-16. View in: PubMed

Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimers Dement. Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimers Dement. 2015 Jan; 11(1):24-31. View in: PubMed

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother. 2015 Jan; 15(1):83-105. View in: PubMed

Idalopirdine for Alzheimer's disease: written in the stars. Lancet Neurol. 2014 Nov; 13(11):1063-1065. View in: PubMed

Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. JAMA Neurol. 2014 Nov; 71(11):1394-404. View in: PubMed

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. View in: PubMed

Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology. 2014 Jul 22; 83(4):364-73. View in: PubMed

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85. View in: PubMed

Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc. 2014 May; 62(5):985-8. View in: PubMed

Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimers Dement. 2014 May; 10(3):349-59. View in: PubMed

Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease. Alzheimers Dement. 2014 Mar; 10(2):247-50. View in: PubMed

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19; 311(7):682-91. View in: PubMed

A new roadmap for drug development for Alzheimer's disease. Nat Rev Drug Discov. 2014 Feb; 13(2):156. View in: PubMed

Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24. View in: PubMed

Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One. 2014; 9(6):e98426. View in: PubMed

Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement. 2013 Sep; 9(5):602-8. View in: PubMed

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44. View in: PubMed

Moderators of outcome in late-life depression: a patient-level meta-analysis. Am J Psychiatry. 2013 Jun; 170(6):651-9. View in: PubMed

Alzheimer disease pharmacologic treatment and treatment research. Continuum (Minneap Minn). 2013 Apr; 19(2 Dementia):339-57. View in: PubMed

Quantifying an amyloid ß model for Alzheimer's disease. Lancet Neurol. 2013 Apr; 12(4):327-8. View in: PubMed

Early intervention with an estrogen receptor ß-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease. J Alzheimers Dis. 2013; 37(2):403-19. View in: PubMed

Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44. View in: PubMed

Ginkgo and AD: key negatives and lessons from GuidAge. Lancet Neurol. 2012 Oct; 11(10):836-7. View in: PubMed

Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology. 2012 Jul 17; 79(3):221-8. View in: PubMed

Caregiver burden, health utilities, and institutional service use in Alzheimer's disease. Int J Geriatr Psychiatry. 2012 Apr; 27(4):382-93. View in: PubMed

Recruitment methods for United States Alzheimer disease prevention trials. J Nutr Health Aging. 2012 Apr; 16(4):331-5. View in: PubMed

Discontinuing donepezil or starting memantine for Alzheimer's disease. N Engl J Med. 2012 Mar 08; 366(10):957-9. View in: PubMed

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. View in: PubMed

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. View in: PubMed

Biomarker positive and negative subjects in the ADNI cohort: clinical characterization. Curr Alzheimer Res. 2012 12; 9(10):1135-41. View in: PubMed

Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012 Jan; 169(1):71-9. View in: PubMed

Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease. J Clin Psychiatry. 2012 Jan; 73(1):121-8. View in: PubMed

Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012; 8(2):121-30. View in: PubMed

Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress. Free Radic Biol Med. 2011 Dec 01; 51(11):2007-17. View in: PubMed

Sertraline for the treatment of depression in Alzheimer disease: genetic influences. J Geriatr Psychiatry Neurol. 2011 Dec; 24(4):222-8. View in: PubMed

Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol. 2011 Nov; 51(11):1587-91. View in: PubMed

Estrogen receptor ß-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause. 2011 Oct; 18(10):1131-42. View in: PubMed

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. View in: PubMed

Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011 Aug; 68(8):991-8. View in: PubMed

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011 Aug; 168(8):831-9. View in: PubMed

Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons. Mol Neurodegener. 2011 Jun 01; 6:37. View in: PubMed

Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)? Int J Geriatr Psychiatry. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011 Jun; 26(6):573-83. View in: PubMed

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011 May; 43(5):436-41. View in: PubMed

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. View in: PubMed

Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011 Feb; 68(2):190-7. View in: PubMed

Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. Int Psychogeriatr. 2011 Feb; 23(1):44-53. View in: PubMed

Anti-aß therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 2011 Jan 27; 69(2):203-13. View in: PubMed

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011 Jan; 68(1):58-66. View in: PubMed

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. J Clin Psychopharmacol. 2010 Dec; 30(6):683-7. View in: PubMed

Organising the language of Alzheimer's disease in light of biomarkers. Lancet Neurol. 2010 Nov; 9(11):1044-5. View in: PubMed

Fixing Alzheimer disease trials by improving process and methods. Curr Alzheimer Res. 2010 Nov; 7(7):564-5. View in: PubMed

Caregiver burden, health utilities, and institutional service costs among community-dwelling patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Oct-Dec; 24(4):380-9. View in: PubMed

Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry. 2010 Oct; 18(10):917-27. View in: PubMed

Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2010 Sep; 6(5):367-77. View in: PubMed

Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Mol Neurodegener. 2010 Apr 13; 5:14. View in: PubMed

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 Apr; 18(4):332-40. View in: PubMed

The potential and limits for clinical trials for early Alzheimer's disease and some recommendations. J Nutr Health Aging. 2010 Apr; 14(4):295-8. View in: PubMed

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010 Mar; 6(2):89-97. View in: PubMed

Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45. View in: PubMed

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009 Dec 16; 302(23):2557-64. View in: PubMed

Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement. 2009 Sep; 5(5):388-97. View in: PubMed

Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7. View in: PubMed

Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis. Int J Geriatr Psychiatry. 2009 May; 24(5):539-44. View in: PubMed

Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry. 2009 May; 166(5):583-90. View in: PubMed

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. View in: PubMed

Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008. " A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging. Alzheimers Dement. 2009 Mar; 5(2):172-9. View in: PubMed

The perils of Alzheimer's drug development. Curr Alzheimer Res. 2009 Feb; 6(1):77-8. View in: PubMed

Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease. Int J Geriatr Psychiatry. 2009 Jan; 24(1):96-105. View in: PubMed

Sociodemographic and clinical correlates of utility scores in Alzheimer's disease. Value Health. 2008 Dec; 11(7):1120-30. View in: PubMed

Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain. 2008 Nov 21; 1:17. View in: PubMed

Ginkgo biloba extract and preventing Alzheimer disease. JAMA. 2008 Nov 19; 300(19):2306-8. View in: PubMed

Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia. Schizophr Res. 2008 Nov; 106(1):33-41. View in: PubMed

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 Oct 15; 300(15):1774-83. View in: PubMed

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008 Jul; 165(7):844-54. View in: PubMed

Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008 Jul; 16(7):558-67. View in: PubMed

Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry. 2008 Jun; 16(6):469-77. View in: PubMed

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. View in: PubMed

Does donepezil improve executive function in patients with CADASIL? Lancet Neurol. Does donepezil improve executive function in patients with CADASIL? Lancet Neurol. 2008 Apr; 7(4):287-9. View in: PubMed

Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008 Feb; 48(2):157-65. View in: PubMed

Prevention therapeutics of dementia. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S122-30. View in: PubMed

American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007 Dec; 164(12 Suppl):5-56. View in: PubMed

Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry. 2007 Nov; 64(11):1259-68. View in: PubMed

Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007 Sep; 6(9):782-92. View in: PubMed

Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease? Curr Alzheimer Res. Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease? Curr Alzheimer Res. 2007 Jul; 4(3):273-6. View in: PubMed

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics. Curr Alzheimer Res. 2007 Jul; 4(3):325-35. View in: PubMed

Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease. " Wuthering forest plots: distinguishing the forest from the plots. Alzheimers Dement. 2007 Jan; 3(1):18-20. View in: PubMed

Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion. 2006 Dec; 6(6):323-30. View in: PubMed

Design of Depression in Alzheimer's Disease Study-2. Am J Geriatr Psychiatry. 2006 Nov; 14(11):920-30. View in: PubMed

Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice. Brain Res. 2006 Oct 20; 1116(1):194-200. View in: PubMed

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006 Oct 12; 355(15):1525-38. View in: PubMed

ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38. View in: PubMed

Open-label extension studies and misinformation. Arch Neurol. 2006 Jul; 63(7):1036; author reply 1036-7. View in: PubMed

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006 Mar; 14(3):191-210. View in: PubMed

Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91. View in: PubMed

The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London? Int J Geriatr Psychiatry. The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London? Int J Geriatr Psychiatry. 2006 Jan; 21(1):9-13. View in: PubMed

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res. 2005 Dec; 2(5):541-51. View in: PubMed

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19; 294(15):1934-43. View in: PubMed

Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment. Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):279-83. View in: PubMed

Mild cognitive impairment. Am J Geriatr Psychiatry. 2005 Aug; 13(8):629-32. View in: PubMed

Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration's systematic review. Alzheimers Dement. 2005 Jul; 1(1):67-71. View in: PubMed

Symptoms of late-life depression: frequency and change during treatment. Am J Geriatr Psychiatry. 2005 Jun; 13(6):520-6. View in: PubMed

Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. Int J Geriatr Psychiatry. 2005 Feb; 20(2):119-27. View in: PubMed

Recognizing and responding to atypical antipsychotic side effects. J Am Med Dir Assoc. 2004 Jul-Aug; 5(4 Suppl):H7-10. View in: PubMed

AD2000: donepezil in Alzheimer's disease. Lancet. 2004 Jun 26; 363(9427):2100-1. View in: PubMed

Estrogen and dementia: insights from the Women's Health Initiative Memory Study. JAMA. 2004 Jun 23; 291(24):3005-7. View in: PubMed

Delay in nursing home placement with donepezil. J Am Geriatr Soc. 2004 Jun; 52(6):1024-6; author reply 1026-7. View in: PubMed

Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents. Evid Based Ment Health. 2004 May; 7(2):47. View in: PubMed

Psychosis of Alzheimer's disease: clinical characteristics and history. J Psychiatr Res. 2004 Jan; 38(1):105-11. View in: PubMed

Evidence-based practices in geriatric mental health care: an overview of systematic reviews and meta-analyses. Psychiatr Clin North Am. 2003 Dec; 26(4):971-90, x-xi. View in: PubMed

Cholinesterase inhibitors for vascular dementia? Lancet Neurol. Cholinesterase inhibitors for vascular dementia? Lancet Neurol. 2003 Nov; 2(11):658-9. View in: PubMed

Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003 Sep; 64(9):1065-74. View in: PubMed

Choosing treatment for Alzheimer's patients and their caregivers. Geriatrics. 2003 Aug; 58 Suppl 1:3-18, 23; quiz 19-22. View in: PubMed

Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am J Geriatr Psychiatry. 2003 Jul-Aug; 11(4):414-25. View in: PubMed

An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry. 2003 Jul; 160(7):1277-85. View in: PubMed

Cholinesterase inhibitors for Alzheimer disease. JAMA. 2003 May 14; 289(18):2359-60; author reply 2360-1. View in: PubMed

A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets. 2003 Feb; 4(2):97-112. View in: PubMed

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull. 2003; 29(1):57-72. View in: PubMed

Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. Expert Rev Neurother. 2003 Jan; 3(1):99-106. View in: PubMed

Evidence-based practices in geriatric mental health care. Psychiatr Serv. 2002 Nov; 53(11):1419-31. View in: PubMed

The increasing power of placebos in trials of antidepressants. JAMA. 2002 Jul 24-31; 288(4):450. View in: PubMed

Galantamine for vascular dementia: some answers, some questions. Lancet. 2002 Apr 13; 359(9314):1265-6. View in: PubMed

Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002 Mar-Apr; 10(2):129-41. View in: PubMed

Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002 Mar-Apr; 10(2):125-8. View in: PubMed

Increasing ethnic minority participation in Alzheimer disease research. Alzheimer Dis Assoc Disord. 2002; 16 Suppl 2:S82-5. View in: PubMed

Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2002; 14(3):303-10. View in: PubMed

Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatr Med. 2001 May; 17(2):337-58. View in: PubMed

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001; 9(4):346-60. View in: PubMed

Antidepressant Treatment of Very Old Patients. Am J Geriatr Psychiatry. 1993 Winter; 1(1):21-29. View in: PubMed

Powered bySC CTSI